Immunotherapy (Checkpoint Inhibitor)

28 molecules in this therapeutic area. Open any product for its details, or send an inquiry directly.

Connect With Us

Immunotherapy (Checkpoint Inhibitor) (12)

Quick filters: Solid Tumour Hematologic Both Name A-Z Name Z-A

Therapeutic Areas

Sort by

Clear all filters

Molecule	Drug Class / Mechanism	Oncology Type
Durvalumab	Anti-PD-L1 mAb	Solid Tumour
Molecule Durvalumab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-PD-L1 mAb
Atezolizumab	Anti-PD-L1 mAb	Solid Tumour
Molecule Atezolizumab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-PD-L1 mAb
Ipilimumab	Anti-CTLA-4 mAb	Solid Tumour
Molecule Ipilimumab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-CTLA-4 mAb
Relatlimab	Anti-LAG-3 mAb	Solid Tumour
Molecule Relatlimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-LAG-3 mAb
Tremelimumab	Anti-CTLA-4 mAb	Solid Tumour
Molecule Tremelimumab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-CTLA-4 mAb
Avelumab	Anti-PD-L1 mAb	Solid Tumour
Molecule Avelumab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-PD-L1 mAb
Botensilimab	Anti-CTLA-4 mAb	Solid Tumour
Molecule Botensilimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-CTLA-4 mAb
Cosibelimab	Anti-PD-L1 Monoclonal Antibody	Solid Tumour
Molecule Cosibelimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-PD-L1 Monoclonal Antibody
Fianlimab	Anti-LAG-3 mAb	Solid Tumour
Molecule Fianlimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-LAG-3 mAb
Ieramilimab	Anti-LAG-3 mAb	Solid Tumour
Molecule Ieramilimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-LAG-3 mAb
Zalifrelimab	Anti-CTLA-4 mAb	Solid Tumour
Molecule Zalifrelimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-CTLA-4 mAb
Sugemalimab	Anti-PD-L1 Monoclonal Antibody	Solid Tumour
Molecule Sugemalimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-PD-L1 Monoclonal Antibody

Durvalumab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-PD-L1 mAb
Atezolizumab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-PD-L1 mAb
Ipilimumab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-CTLA-4 mAb
Relatlimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-LAG-3 mAb
Tremelimumab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-CTLA-4 mAb
Avelumab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-PD-L1 mAb
Botensilimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-CTLA-4 mAb
Cosibelimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-PD-L1 Monoclonal Antibody
Fianlimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-LAG-3 mAb
Ieramilimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-LAG-3 mAb
Zalifrelimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-CTLA-4 mAb
Sugemalimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-PD-L1 Monoclonal Antibody

Product Range

Company

Global Network

Immunotherapy (Checkpoint Inhibitor)

Immunotherapy (Checkpoint Inhibitor) (12)

Durvalumab

Atezolizumab

Ipilimumab

Relatlimab

Tremelimumab

Avelumab

Botensilimab

Cosibelimab

Fianlimab

Ieramilimab

Zalifrelimab

Sugemalimab

Durvalumab

Atezolizumab

Ipilimumab

Relatlimab

Tremelimumab

Avelumab

Botensilimab

Cosibelimab

Fianlimab

Ieramilimab

Zalifrelimab

Sugemalimab